Partnerships, Appointments, New Products, Public Offerings, and Agreements -
Research Report on Questcor Pharmaceuticals, Hologic, IDEXX, Endologix, and
Editor Note: For more information about this release, please scroll to bottom.
New York, December 13, 2013
New York, December 13, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Questcor
Pharmaceuticals, Inc. (NASDAQ: QCOR), Hologic Inc. (NASDAQ: HOLX), IDEXX
Laboratories, Inc. (NASDAQ: IDXX), Endologix Inc. (NASDAQ: ELGX) and
Healthways Inc. (NASDAQ: HWAY). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.
Questcor Pharmaceuticals, Inc. Research Report
On December 9, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced its
partnership with the Child Neurology Foundation (CNF) for supporting the 5^th
annual Infantile Spasms Awareness Week, which is being held this week.
Questcor stated that as part of this education effort, CNF has developed a
website that offers information on Infantile Spasms from leading child
neurologists and shares stories from families dealing with this condition.
Steve Cartt, Chief Operating Officer for Questcor, commented, "Questcor is
privileged to continue its five-year partnership with the Child Neurology
Foundation. The goal of Infantile Spasms Awareness Week is to provide
pediatricians, child neurologists, parents, and caregivers with objective
educational tools which will help increase awareness and understanding of this
very rare form of epilepsy." According to the Company, CNF announced that Dr.
Carolina Amador and the staff at Lincoln Health Center in Corvallis, Oregon,
have been chosen as Infantile Spasms Hero for 2013. The Full Research Report
on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
Hologic Inc. Research Report
On December 9, 2013, Hologic Inc. (Hologic) announced that it has appointed
Jonathan Christodoro and Samuel Merksamer to the Company's Board of Directors,
with immediate effect in accordance with a settlement agreement with Carl C.
Icahn. The Company informed that Mr. Christodoro and Mr. Merksamer are
Managing Directors of Icahn Capital LP, a subsidiary of Icahn Enterprises L.P.
Hologic stated that as a result of these additions, the Company's Board now
comprises of 11 directors, out of which 10 are independent. Hologic added that
it has engaged Dr. Burton Drayer, Chairman and Director of the Department of
Radiology at The Mount Sinai Medical Center, as a scientific advisor to the
Company. In a separate press release on the same day, the Company announced
that Stephen MacMillan has been named President and CEO of Hologic and a
member of its Board of Directors. Hologic stated that Mr. MacMillan succeeds
Jack W. Cumming. The Full Research Report on Hologic Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
IDEXX Laboratories, Inc. Research Report
On December 6, 2013, IDEXX Laboratories, Inc. (IDEXX) announced EliteVision
Digital Imaging System as the latest addition to its line of digital imaging
products, designed specifically for equine veterinarians. According to the
Company, the new DR system is fast and wireless, with state-of-the-art cesium
technology and ImageSuite software, and offers a comprehensive patient view
which allows equine veterinarians to provide their clients with advanced
diagnostic services in the clinic or from the field. The Full Research Report
on IDEXX Laboratories, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
Endologix Inc. Research Report
On December 5, 2013, Endologix Inc. (Endologix) announced the pricing of its
public offering of $75 million aggregate principal amount of convertible
senior notes due 2018 (the Convertible Notes). The Company informed that it
has granted an option to the underwriters for up to an additional $11.25
million aggregate principal amount of Convertible Notes solely to cover
overallotments. Endologix stated that the Convertible Notes will pay
semiannual interest of 2.25% and will be convertible into shares of the
Company's common stock, cash or a combination of cash and shares of the
Company's common stock, at the Company's election, based on the applicable
conversion rate at such time. The Company said that the Convertible Notes will
mature on December 15, 2018, unless repurchased, redeemed or converted in
accordance with their terms prior to such date. Endologix added that before
September 15, 2018, the Convertible Notes will be convertible only upon the
occurrence of certain events and during certain periods, and thereafter, at
any time until the second scheduled trading day immediately preceding the
maturity date. The Company further stated that on or after December 15, 2016,
it may from time to time redeem for cash all or part of the Convertible Notes
in certain circumstances. The Full Research Report on Endologix Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
Healthways Inc. Research Report
On December 5, 2013, Healthways Inc. (Healthways) announced that the Company
and SulAmérica, independent health insurer in Brazil, have signed a new
five-year agreement to launch Latin America's most comprehensive private
health and well-being improvement program for helping SulAmérica's 2 million
members make sustained lifestyle changes while reducing overall healthcare
costs. The Company stated that under the terms of this new agreement,
Healthways and SulAmérica will launch programs in 2014 for helping SulAmérica
members understand their unique well-being scores, then subsequently address
opportunities for improvement through personalized plans and tailored programs
as the five-year agreement progresses. The Full Research Report on Healthways
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE Analysts' Corner
Contact: Joe Thomas, +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.